Full-Time

Director – Global Health Economics and Outcomes Research

Heor

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

Biotechnology
Healthcare

Mid, Senior

Cambridge, MA, USA

70% in-office structure.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Minimum of a Master’s degree in Public Health, Health Services Research, Economics, Epidemiology, Health Policy, or a related discipline.
  • 5+ years of progressive excellence in HEOR, with a successful track record of building and executing high-value-add research agendas.
  • Cross-functional leadership experience, with proven ability to collaborate with stakeholders across medical affairs, field teams, marketing, pricing, contracting, government payers, and other key areas to align scientific, clinical, and commercial objectives.
  • Extensive experience with outcomes-based strategies and tactics, including health economics, patient-reported outcomes, retrospective and prospective data analyses, epidemiology, and health services research, to meet scientific and commercial goals.
  • Strategic leadership in HEOR that has driven measurable business outcomes, including value communication for payers and health authorities to support market access, defend against pricing pressures, and differentiate brands in competitive markets.
  • Strong understanding of vaccine-specific drug development and regulatory pathways, payer reimbursement models, and health policy across multiple regions, with the ability to adapt strategies to different global markets.
  • Excellent communication, presentation, collaboration, and influencing skills across internal and external stakeholders.
Responsibilities
  • Contribute to the design, implementation and management of HEOR studies from concept through publication. HEOR studies may include retrospective database analysis, economic models, prospective research studies, patient-reported outcomes, and payer-focused tools.
  • Lead the design of health economic models that can be used to explain the value of Moderna vaccines to various stakeholders.
  • Collaborate with cross-functional product teams at every stage of development through launch. Partner with the broader vaccines commercial team in presentations to senior internal stakeholders, including our executive committee, and external stakeholders.
  • Work closely with other functions including research and development strategy, epidemiology, regulatory, policy, and medical affairs on the development of programs that support broad access and value.
  • Deliver best-practice project management oversight for all research and study-related activities.
  • Understand the payer landscape and develop networks to engage with thought leaders who can provide input to guide Moderna programs.
  • Represent Moderna at meetings where HEOR discussions and data are required.
  • Be a key player in building HEOR capabilities within Moderna’s vaccines commercial organization, in partnership with newly formed teams that will blaze trails in new markets and grow Moderna at an accelerated pace.
  • Comply with corporate policies and procedures as well as all applicable healthcare laws and regulations.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

54%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?